# ArriVent BioPharma, Inc.: Phase 3 study closed enrollment, 398 enrolled (Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | ArriVent BioPharma, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) |
| NCT ID | NCT05607550 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations |
| Intervention types | drug |
| Target enrollment | 398 |
| Site countries | United States, Australia, Brazil, Canada, China, France, Israel, Italy, Japan, Malaysia, Mexico, Netherlands |
| Posted | 2022-11-07 |
| Planned start | 2023-06-01 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 398 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05607550). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.